These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

90 related articles for article (PubMed ID: 16574718)

  • 41. Avoiding counterproductive results: an experimental pretest of a harm reduction intervention on attitude toward party drugs among users and nonusers.
    Whittingham JR; Ruiter RA; Bolier L; Lemmers L; Van Hasselt N; Kok G
    Subst Use Misuse; 2009; 44(4):532-47. PubMed ID: 19242864
    [TBL] [Abstract][Full Text] [Related]  

  • 42. The predictors and consequences of adolescent amphetamine use: findings from the Victoria Adolescent Health Cohort Study.
    Degenhardt L; Coffey C; Moran P; Carlin JB; Patton GC
    Addiction; 2007 Jul; 102(7):1076-84. PubMed ID: 17567396
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Correlates of ecstasy use in the Swedish general population.
    Abrahamsson T; Hakansson A
    Subst Use Misuse; 2013 Mar; 48(4):353-7. PubMed ID: 23398568
    [TBL] [Abstract][Full Text] [Related]  

  • 44. A behavioural economic analysis of alcohol, amphetamine, cocaine and ecstasy purchases by polysubstance misusers.
    Sumnall HR; Tyler E; Wagstaff GF; Cole JC
    Drug Alcohol Depend; 2004 Oct; 76(1):93-9. PubMed ID: 15380293
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Information processing speed in ecstasy (MDMA) users.
    Wareing M; Fisk JE; Montgomery C; Murphy PN; Chandler MD
    Hum Psychopharmacol; 2007 Mar; 22(2):81-8. PubMed ID: 17295197
    [TBL] [Abstract][Full Text] [Related]  

  • 46. A psycho-economic model of ecstasy consumption and related consequences: a multi-site study with community samples.
    Abdallah AB; Scheier LM; Inciardi JA; Copeland J; Cottler LB
    Subst Use Misuse; 2007; 42(11):1651-84. PubMed ID: 17934989
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Accuracy of current clinical diagnosis in recreational drug-related attendance to the emergency department.
    West E; Cameron P; O'Reilly G; Drummer OH; Bystrzycki A
    Emerg Med Australas; 2008 Aug; 20(4):333-8. PubMed ID: 18782207
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Evidence for selective executive function deficits in ecstasy/polydrug users.
    Fisk JE; Montgomery C
    J Psychopharmacol; 2009 Jan; 23(1):40-50. PubMed ID: 18515461
    [TBL] [Abstract][Full Text] [Related]  

  • 49. No evidence of decrease in cognitive function in users of low-dose Ecstasy.
    Krebs TS; Johansen PØ
    Arch Gen Psychiatry; 2008 Feb; 65(2):236; author reply 236-7. PubMed ID: 18250261
    [No Abstract]   [Full Text] [Related]  

  • 50. Importance of psychiatric confounding in non-randomized studies of heavy ecstasy users.
    Krebs TS; Johansen PØ; Jerome L; Halpern JH
    Psychol Med; 2009 May; 39(5):876-8. PubMed ID: 19215629
    [No Abstract]   [Full Text] [Related]  

  • 51. Polysubstance use and its correlates in adolescent ecstasy users in Taiwan.
    Yen CF; Hsu SY; Cheng CP
    Addict Behav; 2007 Oct; 32(10):2286-91. PubMed ID: 17314013
    [TBL] [Abstract][Full Text] [Related]  

  • 52. The association between the negative effects attributed to ecstasy use and measures of cognition and mood among users.
    Fisk JE; Montgomery C; Murphy PN
    Exp Clin Psychopharmacol; 2009 Oct; 17(5):326-36. PubMed ID: 19803632
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Alcohol, ecstasy, Aldous Huxley's 'soma'.
    Parrott AC
    J Psychopharmacol; 2007 Jan; 21(1):8-9. PubMed ID: 17213249
    [No Abstract]   [Full Text] [Related]  

  • 54. Ecstasy (MDMA, MDA, MDEA, MBDB) consumption, seizures, related offences, prices, dosage levels and deaths in the UK (1994-2003).
    Schifano F; Corkery J; Deluca P; Oyefeso A; Ghodse AH
    J Psychopharmacol; 2006 May; 20(3):456-63. PubMed ID: 16574720
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Sustained effects of ecstasy on the human brain: a prospective neuroimaging study in novel users.
    de Win MM; Jager G; Booij J; Reneman L; Schilt T; Lavini C; Olabarriaga SD; den Heeten GJ; van den Brink W
    Brain; 2008 Nov; 131(Pt 11):2936-45. PubMed ID: 18842607
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Partying on? Life after BZP-based party pills.
    Green JA
    N Z Med J; 2008 Oct; 121(1283):35-42. PubMed ID: 18841183
    [TBL] [Abstract][Full Text] [Related]  

  • 57. [Ecstasy, new psychotropic drugs].
    Djezzar S
    Soins Psychiatr; 2009; (262):35-7. PubMed ID: 19579485
    [No Abstract]   [Full Text] [Related]  

  • 58. Adolescent ecstasy use and depression: cause and effect, or two outcomes of home environment?
    McCann M; Higgins K; Perra O; McCartan C; McLaughlin A
    Eur J Public Health; 2014 Oct; 24(5):845-50. PubMed ID: 24891459
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Who are the new amphetamine users? A 10-year prospective study of young Australians.
    Degenhardt L; Coffey C; Carlin JB; Moran P; Patton GC
    Addiction; 2007 Aug; 102(8):1269-79. PubMed ID: 17624977
    [TBL] [Abstract][Full Text] [Related]  

  • 60. The epidemiology of methamphetamine use and harm in Australia.
    Degenhardt L; Roxburgh A; Black E; Bruno R; Campbell G; Kinner S; Fetherston J
    Drug Alcohol Rev; 2008 May; 27(3):243-52. PubMed ID: 18368605
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.